Current drug treatment of chronic heart failure in clinical routine;Wie wird die chronische herzinsuffizienz heute tatsächlich behandelt?

Deutsche Medizinische Wochenschrift

Volumn 127, Issue 34-35, 2002, Pages 1764-1768

  Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL;

CHRONIC DISEASE; DRUG EFFICACY; HEART FAILURE; HUMAN; PRACTICE GUIDELINE; REVIEW; TREATMENT INDICATION;

EID: 0037163211     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-33545     Document Type: Review

References (34)

1. ACC/AHA Task Force on Practice Guidelines. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: Executive summary. Circulation 2001; 104: 2996-3007
2. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effects of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821-828
3. Avorn J, Soumerai SB. Improving drug therapy decision through educational outreach. N Engl J Med 1983; 308: 1457-1463
4. Barton HV, Michaels AD, Maynard C, Every NR. Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: Data from the National Registry of Myocardial infarction 2. J Am Coll Cardiol 1998; 32: 360-367
5. Beers MH, Dang J, Hasegawa J, Tamai IY. Influence of hospitalization on drug therapy in the elderly. J Am Geriatr Soc 1989; 37: 679-683
6. Berbatis CG, Maher MJ, Plumbridge RJ, Stoehlwinder JU, Zubrick SR. Impact of a drug bulletin on prescribing oral analgesics in a teaching hospital. Am J Hosp Pharm 1982; 38: 98-100
7. Chin MH, Friedmann PD, Cassel CK, Lang RM. Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med 1997; 12: 523-530
8. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hopspitalized patients: excess length of stay, extra costs, and attributable mortality. J Am Med Assoc 1997; 277: 301-306
9. Cohn JN, Johnsons G, Zeische S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M, Bhat G, Goldman S, Fletcher RD, Doherty J, Hughes V, Carson P, Cintron G, Shabetai R, Haakenson C. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310
10. EUROASPIRE Study Group. EUROASPIRE: a European Society of Cardiology survey of secondary prevention of coronary heart disease, principal results. Eur Heart J 1997; 18: 1569-1582
11. Goettler M, Schneeweiss S, Hasford J. Adverse drug reaction monitoring - cost and benefit consideration part II: Cost and preventability of adverse drug reactions leading to hospital admission. Pharmacoepidemiol Drug saf 1997; 6: 79-90(Suppl 3
12. Greer AL. The state of the art versus the state of the science. Int J Technol Assess Health Care 1988; 4: 5-26
13. Grimshaw JM, Russell JT. Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 1993; 342: 1317-1322
14. Grimshaw JM, Russell JT. Achieving health gain through clinical guidelines. II. Ensuring that guidelines change medical practice. Qual Health Care 1994; 3: 45-52
15. Haines A, Feder G. Guidance on guidelines. Writing them is easier than making them work. BMJ 1992; 305: 785-786
16. Hobbs FDR, Jones MI, Allan TF, Wison S, Tobias R. European survey of primary care physician perceptions on heart failure diagnosis and management (Euro-HF). Eur Heart J 2000; 21: 1877-1887
17. Hoppe UC, Erdmann E. für die Kommission für Klinische Kardiologie, Deutsche Gesellschaft für Kardiologie - Herz- und Kreislaufforschung. Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol 2001; 90: 218-241
18. Jassim AI Khaja KA, Sequeira RP, Mathur VS. Rational pharmacotherapy of hypertension in the elderly: analysis of the choice and dosage of drugs. J Clin Pharm Ther 2001; 26: 33-42
19. Kober L, Torp-Pedersen C, Carlsen JE, Bagger H, Eliasen P, Lyngborg K, Videbaek J, Cole DS, Auclert L, Pauly NC, Aliot E, Persson S, Camm AJ. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670-1676
20. Köhler GI, Bode-Böger SM, Busse R, Hoopmann M, Welte T, Böger RH. Drug-drug interactions in medical patients: Effects of in-hospital treatment and relation to multiple drug use. Int J Clin Pharmacol Ther 2000; 38: 504-513
21. Lazarou J, Pomeranz BH, Corey PH. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. J Am Med Assoc 1998; 279: 1200-1205
22. Levy M, Kewitz H, Altwein W, Hillebrand J, Aliakim M. Hospital admissions due to adverse drug reactions: A comparative study from Jerusalem and Berlin. Eur J Clin Pharmacol 1980; 17: 25-31
23. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? N Engl J Med 1989; 321: 1306-1311
24. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril. Circulation 1985; 72: 406-412
25. Popplewell PY, Henschke PJ. Acute admissions to a geriatric assessment unit. Med J Aust 1982; 1: 343-344
26. Rahmahi TM, Longo MD, Rohlfs K, Sheynberg N. Effect of heart failure program on cardiovascular drug utilization and dosage in patients with chronic heart failure. Clin Cardiol 2000; 23: 909-914
27. Remme WJ, Swedberg K for the Task Force for the Diagnosis and treatment of Chronic Heart Failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560
28. Schaffner W, Ray WA, Federspiel CF, Miller WO. Improving antibiotic prescribing in office practice. J Am Med Assoc 1983; 250: 1728-1732
29. Siegel D. The influence of national guidelines on antihypertensive prescribing patterns. Curr Hypertens Rep 2000; 2: 247-252
30. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302
31. Teweleit S, Kuschel U, Hippius M, Goettler M, Bornschein B. Manifestation und Präventionsmöglichkeiten unerwünschter Arzneimittelwirkungen (UAW) in der Pharmakotherapie von Herz- Kreislauferkrankungen. Med Klin 2001; 96: 442-450
32. van Veldhuisen DJ, Charlesworth A, Crijns HJGM, Lie KI, Hampton JR. Differences in drug treatment of chronic heart failure between European countries. Eur Heart J 1999; 20: 666-672
33. Wagdi P, Vuilliomenet A, Kaufmann U, Richter M, Bertel O. Ungenügende Behandlungsdisziplin, Patienteninformation und Medikamentenverschreibung als Ursachen für die Notfallhospitalisation bei chronisch herzinsuffizienten Patienten. Schweiz Med Wschr 1993; 123: 198-112
34. Williamson J, Chopin JM. Adverse reactions to prescribed drugs in the elderly: A multicentre investigation. Age Ageing 1980; 9: 73-90